Uric Acid Lithiasis Treatment via Basifying Agent and Crystallization Inhibitor Combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for uric acid renal lithiasis, such as dietary measures and citrate therapy, are inadequate in effectively preventing uric acid oversaturation and lithiasis, as they often lead to relapse and risk of calcium phosphate lithiasis due to uncontrolled urinary pH increases.
Innovation Solution
A combination of urinary basifying agents like potassium citrate, magnesium citrate, sodium bicarbonate, and saponins as uric acid crystallization inhibitors is used to increase urinary pH in a controlled manner, preventing uric acid oversaturation and lithiasis, while minimizing the risk of calcium phosphate lithiasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of citrate are used to increase urinary pH, then uric acid lithiasis is treated effectively, but urinary pH rises above 6.2 causing calcium phosphate oversaturation and lithiasis
Solution Approach 1:
The patent changes the chemical composition parameters of the treatment by combining citrate (for pH control) with saponins (for crystallization inhibition). This parameter change allows achieving effective uric acid lithiasis treatment while preventing calcium phosphate oversaturation through the synergistic action of the two agents with different mechanisms.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining two different agents: citrate (a basifying agent) and saponins (crystallization inhibitors). This composite material strategy allows the treatment to address multiple aspects of lithiasis prevention simultaneously, resolving the contradiction between effective uric acid treatment and calcium phosphate prevention.
2Reliability
If urinary pH is increased to prevent uric acid oversaturation, then uric acid lithiasis is prevented, but the risk of phosphate lithiasis increases
Solution Approach 1:
Saponins act as an intermediary agent that inhibits crystallization processes. By introducing this intermediary substance, the patent prevents the harmful crystallization effect that would otherwise occur at elevated pH levels, allowing pH increase to be used safely for uric acid prevention without triggering phosphate lithiasis.
Solution Approach 2:
The patent modifies the chemical environment by adding saponins, which change the crystallization parameters of urine. This parameter change enables the system to tolerate higher pH levels without forming phosphate crystals, thus resolving the contradiction between uric acid prevention and phosphate lithiasis risk.
3Reliability
If citrate therapy is used to decrease calcium oxalate calculi formation, then lithiasis is reduced, but relapse rate remains high
Solution Approach 1:
The patent combines citrate with saponins to create a composite treatment that addresses both calcium oxalate and uric acid lithiasis mechanisms. This composite approach extends the duration of protective effect by targeting multiple crystallization pathways simultaneously, thereby reducing relapse rates compared to citrate monotherapy.
Solution Approach 2:
The combination therapy provides continuous protection against multiple types of crystallization through two different mechanisms of action. The saponins provide ongoing crystallization inhibition while citrate maintains pH control, creating a continuous protective effect that reduces relapse risk.
Data Source
Figure 1~2
AI summary
The present invention relates to the use of a separate, sequential or simultaneous combination of at least one urinary basifying agent, with at least one uric acid crystallization inhibitor for basifying urine, thus avoiding the pH value at which renal lithiasis is produced.